Studies Comparing Immunogenicity of Biosimilars and their Reference Products for the Treatment of Plaque Psoriasis.
Abstract
Studies comparing immunogenicity of biosimilars and their reference products that are used for the treatment of plaque psoriasis. (*) indicates when a study reported EU-reference product. ADA percentages indicate the number of patients who developed anti-drug antibodies. NAb percentages indicate the percentage of total patients who developed neutralizing antibodies.
Fields of Study & Subjects
Biosimilars and Bioanalytical Methods
Psoriasis: Treatment and Pathogenesis
Spondyloarthritis Studies and Treatments
Publication details
- Journal / source
- Mendeley Data
- Publication date
- 12 January 2026
- Document type
- Dataset